A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice
| Autor: | Mark J. Shlomchik, Thomas W. Kenniston, Muhammad S. Khan, Emrullah Korkmaz, Nisreen M.A. Okba, Eun Kim, Geza Erdos, Stephen M. Joachim, Stephen C. Balmert, Cara Donahue Carey, Andrea Gambotto, Shaohua Huang, Laura J. Conter, Elena Percivalle, Irene Cassaniti, Louis D. Falo, Bart L. Haagmans, Nadine M. Weisel, Florian Weisel, Fausto Baldanti |
|---|---|
| Přispěvatelé: | Virology |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
COVID-19 Vaccines T-Lymphocytes viruses Immunology Immunity to infection Biology Antibodies Viral SARS‐CoV‐2 Viral vector Adenoviridae 03 medical and health sciences Mice 0302 clinical medicine Immune system Antigen SDG 3 - Good Health and Well-being Immunity COVID‐19 Immunology and Allergy Animals Adenovirus Basic Research Articles B-Lymphocytes Immunity Cellular Mice Inbred BALB C SARS-CoV-2 Immunogenicity Vaccination COVID-19 biochemical phenomena metabolism and nutrition Recombinant DNA vaccines Antibodies Neutralizing Immunity Humoral 030104 developmental biology Immunization Immunoglobulin G Spike Glycoprotein Coronavirus biology.protein Infectious diseases Research Article|Basic Antibody 030215 immunology |
| Zdroj: | European Journal of Immunology, 51(7), 1774-1784. Wiley-VCH European Journal of Immunology |
| ISSN: | 0014-2980 |
| Popis: | Optimal vaccines are needed for sustained suppression of SARS‐CoV‐2 and other novel coronaviruses. Here, we developed a recombinant type 5 adenovirus vector encoding the gene for the SARS‐CoV‐2 S1 subunit antigen (Ad5.SARS‐CoV‐2‐S1) for COVID‐19 immunization and evaluated its immunogenicity in mice. A single immunization with Ad5.SARS‐CoV‐2‐S1 via S.C. injection or I.N delivery induced robust antibody and cellular immune responses. Vaccination elicited significant S1‐specific IgG, IgG1, and IgG2a endpoint titers as early as 2 weeks, and the induced antibodies were long lasting. I.N. and S.C. administration of Ad5.SARS‐CoV‐2‐S1 produced S1‐specific GC B cells in cervical and axillary LNs, respectively. Moreover, I.N. and S.C. immunization evoked significantly greater antigen‐specific T‐cell responses compared to unimmunized control groups with indications that S.C. injection was more effective than I.N. delivery in eliciting cellular immune responses. Mice vaccinated by either route demonstrated significantly increased virus‐specific neutralization antibodies on weeks 8 and 12 compared to control groups, as well as BM antibody forming cells (AFC), indicative of long‐term immunity. Thus, this Ad5‐vectored SARS‐CoV‐2 vaccine candidate showed promising immunogenicity following delivery to mice by S.C. and I.N. routes of administration, supporting the further development of Ad‐based vaccines against COVID‐19 and other infectious diseases for sustainable global immunization programs. Vaccine development against SARS‐CoV‐2 addresses the ongoing challenges posed by this pathogen and ensures preparedness for future outbreaks of coronaviruses. Subcutaneous or intranasal administration of Ad5.SARS‐CoV‐2 S1 results in multifaceted immune responses in mice, including GCs and long‐lived antibody forming cells, representing an attractive COVID‐19 vaccination strategy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text